about
Weight gain after fecal microbiota transplantationTime to Empower Release of Insects Carrying a Dominant Lethal and Wolbachia Against ZikaDifferential Effects of Azithromycin, Doxycycline, and Cotrimoxazole in Ingested Blood on the Vectorial Capacity of Malaria MosquitoesDefining Clinical Excellence in Adult Infectious Disease PracticeHuman Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining ConditionsDid Garin and Bujadoux Actually Report a Case of Lyme Radiculoneuritis?The Impact of Infectious Disease Specialist Consultation for Staphylococcus aureus Bloodstream Infections: A Systematic ReviewSTART or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus InfectionArtemisinin-Based Combination Therapy Versus Quinine or Other Combinations for Treatment of Uncomplicated Plasmodium falciparum Malaria in the Second and Third Trimester of Pregnancy: A Systematic Review and Meta-AnalysisMinocycline as A Substitute for Doxycycline in Targeted Scenarios: A Systematic ReviewFar East Scarlet-Like Fever: A Review of the Epidemiology, Symptomatology, and Role of Superantigenic Toxin: Yersinia pseudotuberculosis-Derived Mitogen AIntegrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early TreatmentDesigning and Interpreting Limiting Dilution Assays: General Principles and Applications to the Latent Reservoir for Human Immunodeficiency Virus-1The Control of Methicillin-Resistant Staphylococcus aureus Blood Stream Infections in EnglandAcute Phase Reactants in Infections: Evidence-Based Review and a Guide for CliniciansHepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion.Adenosine Analog NITD008 Is a Potent Inhibitor of Zika VirusWidespread Rift Valley Fever Emergence in Senegal in 2013–2014Incidence of herpes simplex virus type 2 infections in Africa: a systematic reviewA Case of Meningococcal Pyomyositis in an Otherwise Healthy AdultProbiotics in Human Immunodeficiency Virus Infection: A Systematic Review and Evidence Synthesis of Benefits and RisksVitamin D as Adjunctive Host-Directed Therapy in Tuberculosis: A Systematic ReviewHow to Pitch an Antibiotic Stewardship Program to the Hospital C-SuiteInvasive Aspergillus Sinusitis in Human Immunodeficiency Virus Infection: Case Report and Review of the LiteratureOngoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory AgentsTreatment Options for Carbapenem-Resistant Enterobacteriaceae InfectionsImpact of Decentralized Care and the Xpert MTB/RIF Test on Rifampicin-Resistant Tuberculosis Treatment Initiation in Khayelitsha, South AfricaZika Virus Causing Encephalomyelitis Associated With ImmunoactivationImproving Influenza and Pneumococcal Vaccination Rates in Ambulatory Specialty PracticesA Novel Rapidly Growing Mycobacterium Species Causing an Abdominal Cerebrospinal Fluid Pseudocyst InfectionTen-Year Experience of Cutaneous and/or Subcutaneous Infections Due to Coelomycetes in FrancePediatric Drug Nitazoxanide: A Potential Choice for Control of Zika.Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial.Reactive School Closure During Increased Influenza-Like Illness (ILI) Activity in Western Kentucky, 2013: A Field Evaluation of Effect on ILI Incidence and Economic and Social Consequences for FamiliesBurden of Nursing Home-Onset Clostridium difficile Infection in the United States: Estimates of Incidence and Patient Outcomes.Infectious Disease Physician Assessment of Hospital Preparedness for Ebola Virus Disease.Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial.Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant.Influenza hospitalizations among american indian/alaska native people and in the United States general population.Rotavirus Vaccine Schedules and Vaccine Response Among Infants in Low- and Middle-Income Countries: A Systematic Review.
P1433
Q22305013-C3D242BE-8108-46A4-8401-B1E716D5E223Q26314587-5AD4B117-1385-4193-A31A-4D5156A0D38AQ26315272-0DEB6B09-C343-4994-9F93-5D5A96D3543AQ26700043-42D85AD0-8BF7-4D5C-9BFE-27381F0FDFECQ26740117-A5CCF99A-C9C1-4FEE-82D6-5AC58E55431EQ26740121-D50DE115-81A3-4641-80CE-321B113500FBQ26751492-68633CBA-826D-4D2F-A558-579A7A916EAAQ26753830-C3B79A7C-BAAF-49B4-8835-5240E4836D20Q26770713-48F4C377-3228-4D24-B892-2A06DBC40B77Q26771470-09840A7B-898A-4ED3-A8BA-CD914B765D31Q26773071-8EFFE438-DCC1-46A2-BD1F-F29C4110F759Q26778085-2F46FA9D-6A03-49D6-9765-3AA359FEE213Q26781918-14B49FAA-AC1B-43E2-8FAF-D5E1EEE646EAQ26783950-3E4A75C0-277C-4BD3-B7EB-BF3B21605B6FQ26799899-9C6054BC-3CA2-44CB-A90F-A11B49B6A37DQ27321791-8AC1FD24-C086-41DA-9B5D-663BC693FCC9Q27463110-1E3CAE25-D4CB-46B3-ACA3-96947B23A8D3Q27468927-21357096-58C8-4749-A353-895AFA121B44Q27690876-C4F58283-F849-46ED-A5FF-C260D8526B6AQ28069252-7C664F37-D325-4069-9894-7F7858F580E6Q28069649-E45E0A26-11FD-4FBD-A1E5-C79A9AC109D2Q28071387-2E724A93-5DCE-4D5F-B604-0C3991FABB17Q28075985-917983A0-799A-4A19-824A-BFA0E8FA60CEQ28078679-A9DE8FAC-DB3E-4C21-BE0F-6CB27421F48BQ28079455-24E9C2B7-7C37-48A4-95DB-C59FD2E29940Q28082546-EF55E328-7C05-4531-A67A-3700CB4AA889Q28394564-C450B368-3AF4-420B-8DA5-033D91EAB0BAQ28595389-E2EF8D8A-591C-447A-8143-005803ED3942Q28607046-CC51E3B8-BA7E-4A61-BED9-DED4A8F22C9EQ28822613-B7754895-0817-4CB9-833F-2715BFF8E1A0Q28830278-C9B3976C-2E36-4F08-A18E-27B840B74953Q30145642-891BA218-F7C9-4A66-8FDF-8C52F5DD00F4Q30151079-EB6A71B2-FB48-420E-B41F-ADA692A8AF28Q30151672-7DC4C1E7-4FAC-4B5B-98E3-42A5D2B124E8Q30196898-8BE51C85-AED9-4DB1-AF4F-68BC8731853AQ30203126-2BC2648A-D92B-4D42-84E1-69354C5EAEEFQ30204573-724ACD6A-D8BF-40E9-8319-829160796075Q30204578-2903ABE8-5E03-4945-947C-202E31181AD0Q30204584-8E5A7BF3-5ABC-406E-8D1D-70F41A80DABBQ30234306-0E431AA0-7951-4447-95AF-D838DE09AE46
P1433
description
journal
@en
revista científica
@es
wetenschappelijk tijdschrift van Oxford University Press
@nl
wissenschaftliche Fachzeitschrift
@de
name
Open forum infectious diseases
@ast
Open forum infectious diseases
@en
Open forum infectious diseases
@es
Open forum infectious diseases
@nl
type
label
Open forum infectious diseases
@ast
Open forum infectious diseases
@en
Open forum infectious diseases
@es
Open forum infectious diseases
@nl
altLabel
Open Forum Infect Dis
@en
Open Forum Infectious Diseases
@en
prefLabel
Open forum infectious diseases
@ast
Open forum infectious diseases
@en
Open forum infectious diseases
@es
Open forum infectious diseases
@nl
P31
P3181
P1055
P1156
21100468501
P1277
P1476
Open forum infectious diseases
@en